PT1558643E - Apresentação de um receptor das células t - Google Patents

Apresentação de um receptor das células t Download PDF

Info

Publication number
PT1558643E
PT1558643E PT03811009T PT03811009T PT1558643E PT 1558643 E PT1558643 E PT 1558643E PT 03811009 T PT03811009 T PT 03811009T PT 03811009 T PT03811009 T PT 03811009T PT 1558643 E PT1558643 E PT 1558643E
Authority
PT
Portugal
Prior art keywords
cell receptor
tcr
receptor display
cell
display
Prior art date
Application number
PT03811009T
Other languages
English (en)
Inventor
Bent Karsten Jakobsen
Torben Bent Andersen
Peter Eamon Molloy
Yi Li
Jonathan Michael Boulter
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0226227A external-priority patent/GB0226227D0/en
Priority claimed from GB0301814A external-priority patent/GB0301814D0/en
Priority claimed from GB0304067A external-priority patent/GB0304067D0/en
Priority claimed from GB0311397A external-priority patent/GB0311397D0/en
Priority claimed from GB0316356A external-priority patent/GB0316356D0/en
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of PT1558643E publication Critical patent/PT1558643E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT03811009T 2002-11-09 2003-10-30 Apresentação de um receptor das células t PT1558643E (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0226227A GB0226227D0 (en) 2002-11-09 2002-11-09 Receptors
GB0301814A GB0301814D0 (en) 2003-01-25 2003-01-25 Substances
GB0304067A GB0304067D0 (en) 2003-02-22 2003-02-22 Substances
US46304603P 2003-04-16 2003-04-16
GB0311397A GB0311397D0 (en) 2003-05-16 2003-05-16 Substances
GB0316356A GB0316356D0 (en) 2003-07-11 2003-07-11 Substances

Publications (1)

Publication Number Publication Date
PT1558643E true PT1558643E (pt) 2009-08-24

Family

ID=32315013

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03811009T PT1558643E (pt) 2002-11-09 2003-10-30 Apresentação de um receptor das células t

Country Status (14)

Country Link
US (3) US8741814B2 (pt)
EP (2) EP1558643B1 (pt)
JP (1) JP4975324B2 (pt)
AT (1) ATE432290T1 (pt)
AU (2) AU2003276403B2 (pt)
CA (1) CA2505558C (pt)
DE (1) DE60327795D1 (pt)
DK (1) DK1558643T3 (pt)
ES (1) ES2327229T3 (pt)
IL (1) IL167745A (pt)
NO (1) NO333840B1 (pt)
NZ (2) NZ570811A (pt)
PT (1) PT1558643E (pt)
WO (1) WO2004044004A2 (pt)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756278B1 (en) * 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
GB0411771D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0411773D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
DE602005014230D1 (de) * 2004-05-26 2009-06-10 Immunocore Ltd Hochaffine telomerase-t-zellen-rezeptoren
GB0417954D0 (en) * 2004-08-12 2004-09-15 Avidex Ltd Cellulat TCR ligand assay method
MX2007003910A (es) * 2004-10-01 2007-06-07 Avidex Ltd Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
EP1812574A2 (en) * 2004-11-18 2007-08-01 Avidex Limited Soluble bifunctional proteins
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
WO2006090905A1 (ja) * 2005-02-24 2006-08-31 Nippon Sheet Glass Company, Limited 窓用板状体及び窓用板状体を窓用開口部から取り外す方法
EP2275441B8 (en) * 2005-04-01 2016-10-19 Immunocore Ltd. High affinity HIV T cell receptors
GB0524477D0 (en) * 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
EP1885754B1 (en) * 2005-05-25 2011-02-09 Immunocore Ltd. T cell receptors which specifically bind to vygfvracl-hla-a24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
EP1899374A1 (en) * 2005-06-20 2008-03-19 Medigene Limited Synthetic ligands of peptide-mhc complexes, or cd1-antigen complexes
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
KR101441693B1 (ko) 2005-10-18 2014-09-25 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및사용 방법
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008037943A1 (en) * 2006-09-29 2008-04-03 Medigene Limited Cells transformed with nucleic acid encoding ny-eso t cell receptors
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
EP2179740B1 (en) * 2007-08-07 2014-10-08 Mg Pharma Inc. Anti-hypertensive agent
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
SG190661A1 (en) 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
GB0816096D0 (en) * 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2598528A1 (en) 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
CN104684926B (zh) * 2012-07-27 2022-04-08 伊利诺伊州大学理事会 工程化t细胞受体
US11105802B2 (en) 2012-12-10 2021-08-31 Seattle Children's Hospital Cell-free biofragment compositions and related systems, devices, and methods
GB201223172D0 (en) * 2012-12-21 2013-02-06 Immunocore Ltd Method
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2014200933A1 (en) * 2013-06-12 2014-12-18 Arizona Board Of Regents On Behalf Of Arizona State University Obtaining information from single cells within populations using dna origami nanostructures
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
BR112016021004A2 (pt) * 2014-03-14 2018-01-23 Immunocore Limited biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
EP3216801B1 (en) * 2014-11-07 2020-01-01 Guangdong Xiangxue Life Sciences, Ltd. Soluble heterodimeric t cell receptor, and preparation method and use thereof
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
CA2987871A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
JP6568239B2 (ja) * 2015-06-01 2019-08-28 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体ライブラリ
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
HRP20202019T1 (hr) 2015-07-01 2021-04-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
MA51531A (fr) 2015-07-06 2020-11-11 Immatics Biotechnologies Gmbh Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP3347374A1 (en) 2015-09-09 2018-07-18 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
WO2017109110A1 (en) 2015-12-23 2017-06-29 Medigene Immunotherapies Gmbh Dendritic cell composition
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN116731156A (zh) 2016-03-16 2023-09-12 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体
DK3430037T3 (da) 2016-03-16 2022-11-21 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
CR20180530A (es) 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
ES2914648T3 (es) 2016-04-08 2022-06-15 Immunocore Ltd Receptores de células T
WO2017180738A1 (en) * 2016-04-12 2017-10-19 Medimmune, Llc Immune repertoire mining
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
PT3464380T (pt) 2016-06-02 2025-02-06 Immunocore Ltd Regime de dosagem para proteína de fusão de tcr específico de gp100 - scfv anti-cd3
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN107987155A (zh) * 2016-10-27 2018-05-04 中国科学院广州生物医药与健康研究院 识别sage1抗原短肽的t细胞受体
EP3535288A1 (en) 2016-11-07 2019-09-11 Immunocore Limited Peptides
US12227578B2 (en) 2016-11-11 2025-02-18 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
SI3580561T1 (sl) 2017-02-12 2024-04-30 Biontech Us Inc. Metode, osnovane na hla, in njihove sestave ter uporabe
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
AU2018251839B2 (en) 2017-04-10 2022-06-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
MX2019012398A (es) 2017-04-18 2020-09-25 Broad Inst Inc Composiciones para detectar secreciones y metodos de uso.
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
EP4316597A3 (en) 2017-07-07 2024-11-06 immatics biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
EP4026554A1 (en) 2017-08-03 2022-07-13 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR20200066616A (ko) 2017-09-21 2020-06-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
KR20250029294A (ko) 2017-09-22 2025-03-04 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
EA202090812A1 (ru) * 2017-09-22 2020-08-07 Уси Байолоджикс Аэлэнд Лимитед Новые биспецифические полипептидные комплексы
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
AU2019249215B2 (en) 2018-04-06 2026-02-19 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
EP3876956A4 (en) 2018-11-08 2022-12-28 The Regents of The University of California SYSTEMS AND METHODS FOR TARGETING CANCER CELLS
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CN114072166A (zh) 2019-05-14 2022-02-18 泰加生物工艺学公司 用于治疗t细胞耗竭的组合物和方法
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
EP4090365A1 (en) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
CN113684258B (zh) 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023156663A1 (en) 2022-02-20 2023-08-24 Immunocore Limited Hiv-specific binding molecules and tcr
US20250205324A1 (en) 2022-03-31 2025-06-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
TW202417476A (zh) 2022-08-18 2024-05-01 英商英美偌科有限公司 Ｔ細胞受體及其融合蛋白
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
EP4646268A1 (en) 2023-01-06 2025-11-12 Immunocore Limited Binding molecules against a piwil1 peptide-hla complex
WO2024146951A1 (en) 2023-01-06 2024-07-11 Immunocore Limited Binding molecules against a prame peptide-hla complex
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
GB202306345D0 (en) 2023-04-28 2023-06-14 Immunocore Ltd Binding molecules
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
GB202406837D0 (en) 2024-05-14 2024-06-26 Immunocore Ltd Screening methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080840A (en) * 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1998039482A1 (en) * 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
WO1998048008A1 (en) * 1997-04-23 1998-10-29 Plueckthun Andreas Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
GB9718455D0 (en) 1997-09-02 1997-11-05 Mcgregor Duncan P Chimeric binding peptide library screening method
EP1019439B1 (en) 1997-10-02 2011-11-16 Altor BioScience Corporation Soluble single-chain t-cell receptor proteins
DE69827834T2 (de) 1997-10-14 2005-12-08 The Penn State Research Foundation Verfahren und gerät zum ausbalancieren der füllung von spritzformen
US6759243B2 (en) * 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
JP4382881B2 (ja) * 1998-03-05 2009-12-16 アルトー バイオサイエンス コーポレーション バクテリオファージ外殻タンパク質および一本鎖ｔ細胞レセプターを含んでなる融合タンパク質
AU758949B2 (en) * 1998-05-19 2003-04-03 Avidex Limited Multivalent T cell receptor complexes
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU781396B2 (en) 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
EP1118661A1 (en) * 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
AU2001232204A1 (en) * 2000-02-22 2001-09-03 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
IL136459A0 (en) * 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
WO2002092780A2 (en) * 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
EP1421115B1 (en) * 2001-08-31 2005-03-02 Avidex Limited Soluble t cell receptor

Also Published As

Publication number Publication date
NO20052743D0 (no) 2005-06-08
US20140349855A1 (en) 2014-11-27
EP1558643A2 (en) 2005-08-03
US9279122B2 (en) 2016-03-08
US20140371085A1 (en) 2014-12-18
US20100113300A1 (en) 2010-05-06
AU2010202953A1 (en) 2010-08-05
US8741814B2 (en) 2014-06-03
EP1558643B1 (en) 2009-05-27
AU2003276403A1 (en) 2004-06-03
NZ539226A (en) 2008-09-26
EP2048159B1 (en) 2014-01-01
CA2505558A1 (en) 2004-05-27
WO2004044004A2 (en) 2004-05-27
ES2327229T3 (es) 2009-10-27
ATE432290T1 (de) 2009-06-15
US9447410B2 (en) 2016-09-20
NO20052743L (no) 2005-08-08
DE60327795D1 (de) 2009-07-09
AU2003276403B2 (en) 2010-04-15
EP2048159A1 (en) 2009-04-15
NO333840B1 (no) 2013-09-30
JP2006525790A (ja) 2006-11-16
DK1558643T3 (da) 2009-09-07
IL167745A (en) 2010-12-30
AU2010202953B2 (en) 2012-10-04
WO2004044004A3 (en) 2004-09-30
JP4975324B2 (ja) 2012-07-11
NZ570811A (en) 2009-11-27
CA2505558C (en) 2013-07-02

Similar Documents

Publication Publication Date Title
PT1558643E (pt) Apresentação de um receptor das células t
EP1172792A3 (en) Display apparatus capable of adjusting subfield number according to ambient brightness
CA2472692A1 (en) Apparatus for separating material
EP1280049A3 (en) Printing portable-selected information
AU3405299A (en) Multifunction tool
CA2472038A1 (en) An apparatus for separating material
WO2002099594A3 (en) A deployment console for use with a computer system deploying software to remotely located devices
WO2000077591A3 (en) Tactile interface system for electronic data display system
AU2002337082A1 (en) Housing case for video set comprising a video player or game console type electronic console, and associated independent display
EP1522912A3 (en) Manual-mode operating system for robot
WO2007041545A3 (en) Selecting high quality reviews for display
GB2403526A (en) Shale shaker
AUPN802296A0 (en) An input device for controlling a pointer on the screen of a computer
WO2003000853A3 (en) Protein aggregation assays and uses thereof
AU2003256833A1 (en) Browsing an electronic catalog having product images displayed therewithin
AU6887098A (en) Adjustable screen lap-top computer
BR9802508A (pt) Formulação de compostos de cloreto de polivinilo livre de metais pesados para isolamento de cabo primário automotor de parede delgada
CA2230977A1 (en) Vehicle diagnosing apparatus
DE69824020D1 (de) Markierungsvorrichtung für ein elektronisches darstellungsbrett
EP1262984A3 (en) File storing apparatus with file list display function
GB2388993A (en) Illumination apparatus
TW200519515A (en) Method and apparatus for mapping image shapes for a display device
AU8130794A (en) Optometric test chart for computer screen simulation
AU2003287453A1 (en) Antibodies specific for phosphorylated insulin receptor substrate-1/2 (ser 1101/ser1149) and uses thereof
EP0916943A3 (en) Portable non-destructive inspection device and support casing therefor